The effects of targeted immune-regulatory strategies on tumor-specific T-cell responses in vitro
- 9 November 2020
- journal article
- research article
- Published by Springer Nature in Cancer Immunology, Immunotherapy
- Vol. 70 (6) , 1771-1776
Abstract
Background Immune-related adverse events (IrAEs) are auto-immune reactions associated with immune checkpoint inhibitor-based therapy (ICI). Steroids are currently the first-line option for irAE management; however, recent studies have raised concerns regarding their potential impairment of tumor-specific immune responses. In this study, we investigated the in vitro effects of commonly used irAE treatment drugs on the anti-tumor activity of tumor-infiltrating lymphocytes (TILs). Methods Impairment of anti-tumor immune responses by four drugs (antibodies: vedolizumab and tocilizumab; small molecules: mycophenolate mofetil and tacrolimus) reported to be effective in treating irAEs was tested at clinically relevant doses in vitro and compared to a standard moderate dose of corticosteroids (small molecules) or infliximab (antibodies). TIL responses against autologous tumor cell lines, in the presence or absence of irAE drugs, were determined by flow cytometry (short-term tumor-specific T-cell activation) or xCELLigence (T-cell-mediated tumor killing). Results None of the tested antibodies influenced T-cell activation or T-cell-mediated tumor killing. Low-dose mycophenolate and tacrolimus did not influence T-cell activation, whereas higher doses of tacrolimus (> 1 ng/ml) impaired T-cell activation comparably to dexamethasone. All tested small molecules impaired T-cell-mediated tumor killing, with high-dose tacrolimus reducing killing at levels comparable to dexamethasone-mediated inhibition. In addition, mycophenolate and tacrolimus alone also demonstrated anti-proliferative effects on tumor cells. Conclusions These data support clinical testing of targeted immune-regulatory strategies in the initial phase of irAE management, as a potential replacement for corticosteroids.Keywords
Funding Information
- Kræftens Bekæmpelse (R184-A11806)
- Kræftens Bekæmpelse (Empowering Cancer Immunotherapy in Denmark)
This publication has 26 references indexed in Scilit:
- Endogenous Glucocorticoid Signaling Regulates CD8+ T Cell Differentiation and Development of Dysfunction in the Tumor MicroenvironmentImmunity, 2020
- Immune-related adverse events of checkpoint inhibitorsNature Reviews Disease Primers, 2020
- Vedolizumab trough level monitoring in inflammatory bowel disease: a state-of-the-art overviewBMC Medicine, 2019
- Differential effects of corticosteroids and anti‐TNF on tumor‐specific immune responses: implications for the management of irAEsInternational Journal of Cancer, 2018
- Fundamental Mechanisms of Immune Checkpoint Blockade TherapyCancer Discovery, 2018
- T cells isolated from patients with checkpoint inhibitor-resistant melanoma are functional and can mediate tumor regressionAnnals of Oncology, 2018
- The Cancer Immunotherapy RevolutionScience, 2018
- Long-Lasting Complete Responses in Patients with Metastatic Melanoma after Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes and an Attenuated IL2 RegimenClinical Cancer Research, 2016
- Immune-related adverse events with immune checkpoint blockade: a comprehensive reviewEuropean Journal of Cancer, 2016
- Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR–induced stop signalNature Immunology, 2009